Guardant Health, Inc.
GH · XNASCIK 1576280fmd_1327TTNQ03WERJ9G82X0Y3FA44Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 38 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 25 | 50 | 91 | 214 | 287 | 374 | 450 | 564 | 739 | 982 |
| Cost of revenue | – | – | – | – | – | – | – | 227 | 290 | 349 |
| Gross profit | – | – | – | – | – | – | – | 337 | 449 | 633 |
| Research and development | 11 | 26 | 51 | 86 | 150 | 263 | 374 | 367 | 348 | 364 |
| Selling, general and administrative | 36 | 69 | 90 | 140 | 299 | 399 | 464 | 451 | 545 | 706 |
| Operating income | (44) | (77) | (93) | (82) | (255) | (411) | (544) | (565) | (444) | (437) |
| Interest expense | 3 | 3 | 1 | 1 | 5 | 3 | 3 | 3 | 3 | 4 |
| Interest and investment income | 1 | 2 | 5 | 14 | 10 | 4 | 6 | 35 | 54 | 34 |
| Other non-operating income (expense) | (0) | (1) | 5 | 0 | 4 | 25 | (13) | 53 | (43) | (10) |
| Income before taxes | (46) | (83) | (84) | (70) | (246) | (384) | (653) | (479) | (435) | (418) |
| Income tax expense | 0 | 0 | 0 | (2) | 0 | 0 | 1 | 1 | 1 | (1) |
| Net income from continuing operations | (46) | (83) | (84) | (68) | (246) | (385) | (655) | (479) | (436) | (416) |
| Net income | (46) | (83) | (85) | (76) | (246) | (385) | (655) | (479) | (436) | (416) |
| Net income to common shareholders | (46) | (89) | (85) | (76) | (254) | (406) | (655) | (479) | (436) | (416) |